Target intelligence / Profile preview

Epitope on Leishmania amazonensis promastigotes

Molecular classification
Surface antigen, Glycoprotein, Lipophosphoglycan, Enzyme (Metalloprotease), Other
01

Overview

Epitope on Leishmania amazonensis promastigotes refers to the various antigenic determinants found on the surface of the promastigote stage of the protozoan parasite Leishmania amazonensis. These epitopes are primarily associated with major surface molecules such as Glycoprotein 63 (gp63), a zinc-metalloprotease, and Lipophosphoglycan (LPG), which are essential for the parasite's survival and infectivity within the host. These surface structures facilitate attachment to host macrophages, modulate host signaling to suppress immune responses, and protect the parasite from complement-mediated lysis. In drug and vaccine development, these epitopes are targeted to elicit protective immunity, particularly in the design of whole-parasite or recombinant vaccines like the Leishmania amazonensis antigen (LaAg). While research has identified specific monoclonal antibodies that recognize these sites, therapeutic challenges remain, including the potential for antigenic variation and the complexity of the host's cellular immune response required for parasite clearance.

Other names
Leishmania amazonensis promastigote surface antigenLeishmania amazonensis antigenLaAgPromastigote Surface Antigen (PSA)Major Surface Protease (MSP/gp63)Lipophosphoglycan (LPG)
02

Mechanism of action

Induction of protective humoral and cellular immune responses (vaccines); Neutralization of parasite surface molecules to prevent host cell entry or opsonization for phagocytic clearance (antibodies).

03

Biological functions

Host cell attachmentImmune evasionProteolysisSignal transductionProtection against complement-mediated lysisIntracellular survival
04

Disease associations

Cutaneous leishmaniasisMucocutaneous leishmaniasisDiffuse cutaneous leishmaniasisInfection
05

Safety considerations

Molecular mimicry leading to potential autoimmune cross-reactivityHypersensitivity reactions to vaccine componentsAntigenic variation leading to immune escapePoor immunogenicity in immunocompromised patients
06

Interacting drugs

Leishmania amazonensis antigen (LaAg) vaccine

3 more in the full profile.

07

Biomarkers

Anti-Leishmania antibody titersInterferon-gamma (IFN-γ) productionDelayed-type hypersensitivity (DTH) responseParasite load reduction

Beyond the preview

Go deeper on Epitope on Leishmania amazonensis promastigotes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epitope on Leishmania amazonensis promastigotes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call